EODData

MEMBERSHIP REGISTER LOG IN

ASX, PIQ:

24 Oct 2025
LAST:

0.3500

CHANGE:
 0.01		OPEN:
0.3600		HIGH:
0.3600		ASK:
0.3250		VOLUME:
50.6K
CHG(%):
1.41		PREV:
0.3550		LOW:
0.3500		BID:
0.3100		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
24 Oct 250.36000.36000.35000.350050.6K
23 Oct 250.35500.36000.34500.355099.5K
22 Oct 250.35500.36000.35000.350096.9K
21 Oct 250.37000.37000.34500.3500412.1K
20 Oct 250.39500.39500.34500.3700434.8K
17 Oct 250.41500.41500.38000.3850201.8K
16 Oct 250.39000.41500.38000.4150382.8K
15 Oct 250.37500.42000.37500.3800179.2K
14 Oct 250.37000.39500.36750.3900305.4K
13 Oct 250.35500.37000.35000.3650113.1K

COMPANY PROFILE

Name:
About:Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company's products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment. It is also developing diagnostic tests for that includes DKD - T1D, that is under clinical phase for type 1 diabetes, diabetic retinopathy, and diabetic neuropathy; Asthma and COPD, which has completed proof-of-concept study trials for asthma and chronic obstructive pulmonary disease; Plant Dieback, that is under development phase for phytophthora dieback; Diabetic Retinopathy, which has completed discovery phase for sight-threatening retinopathy; and Diabetic Neuropathy, that is under research phase to investigate predictive biomarkers for diabetic neuropathy. The company also offers analytical services, such as specialist contract research focusing on biomarker discovery, biosimilars quality control, and pharmacokinetic testing for clinical trials. It has strategic collaboration with Harry Perkins Institute of Medical Research, Bioplatforms Australia, The University of Western Australia, Australian Research Council Training Centre, and the Australian Centre. Proteomics International Laboratories Ltd was founded in 2001 and is based in Perth, Australia.
Sector:Healthcare
Industry:Biotechnology
Address:QEII Medical Centre, Perth, WA, Australia, 6009
Website:https://www.proteomics.com.au
ISIN:AU000000PIQ0
FIGI:BBG007HW1FZ2

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:0.361.4%
MA10:0.376.0%
MA20:0.376.1%
MA50:0.343.1%
MA100:0.363.4%
MA200:0.4323.1%
RSI14:40.91
WPR14:-100.00 
MTM14:-0.07
ROC14:-0.16 
ATR:0.03 
Week High:0.4218.6%
Week Low:0.351.4%
Month High:0.4220.0%
Month Low:0.3123.1%
Year High:0.84140.0%
Year Low:0.2922.8%
Volatility:54.01